Drug Profile
Indacaterol/mometasone - Novartis
Alternative Names: Atectura; Atectura Breezhaler; IND/MF; Mometasone furoate/indacaterol acetate; Mometasone/indacaterol; QMF Twisthaler®; QMF-149Latest Information Update: 30 May 2023
Price :
$50
*
At a glance
- Originator Novartis; Schering-Plough
- Developer Merck & Co; Novartis
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
- Phase III Chronic obstructive pulmonary disease
Most Recent Events
- 11 May 2023 Phase-III clinical trials in Asthma (In children, Treatment-experienced) in South Africa (Inhalation) (NCT05562466)
- 01 Oct 2022 Novartis Pharmaceuticals plans a phase III trial for Asthma (Child, Treatment experienced) , NCT05562466)
- 29 Apr 2022 Novartis announces intention to file regulatory applications for Asthma (In children, In adolescents) in or after 2027 (Novartis pipeline, April 2022)